Centiva Capital LP Sells 988 Shares of AstraZeneca PLC (NASDAQ:AZN)

Centiva Capital LP decreased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 13.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,563 shares of the company’s stock after selling 988 shares during the period. Centiva Capital LP’s holdings in AstraZeneca were worth $430,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Capital International Investors grew its position in shares of AstraZeneca by 1.9% in the 4th quarter. Capital International Investors now owns 37,507,159 shares of the company’s stock worth $2,457,706,000 after buying an additional 686,008 shares during the last quarter. Bank of America Corp DE increased its position in shares of AstraZeneca by 189.3% during the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company’s stock worth $1,574,247,000 after purchasing an additional 15,722,197 shares in the last quarter. Franklin Resources Inc. increased its position in shares of AstraZeneca by 1.9% during the fourth quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company’s stock worth $1,276,367,000 after purchasing an additional 357,894 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of AstraZeneca by 3.1% during the 4th quarter. Jennison Associates LLC now owns 15,430,963 shares of the company’s stock valued at $1,011,037,000 after purchasing an additional 466,416 shares during the last quarter. Finally, Sanders Capital LLC boosted its position in shares of AstraZeneca by 1.4% in the 4th quarter. Sanders Capital LLC now owns 15,186,692 shares of the company’s stock worth $995,032,000 after purchasing an additional 212,301 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.4 %

AZN stock opened at $67.57 on Friday. The company has a market capitalization of $209.55 billion, a P/E ratio of 29.90, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The firm’s fifty day simple moving average is $71.33 and its 200-day simple moving average is $69.70. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period last year, the firm earned $2.06 EPS. As a group, equities research analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research analyst reports. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Thursday, February 13th. Morgan Stanley assumed coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They issued an “overweight” rating for the company. Finally, BNP Paribas initiated coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $88.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.